Versus

In September 2026, Versus concentrated nearly three-quarters of sales across Flower at 28.36% share and Vapor Pens at 22.74%, both contracting sharply year over year at -76.41% and -65.76% and falling month over month at -28.53% and -27.99%, respectively; meanwhile, Pre-Roll held 21.62% share with a comparatively smaller YoY decline of -6.95% and a -10.63% MoM slide. Beverage rose to 20.82% share with a -4.52% YoY change and a 2.32% MoM lift, while Concentrates at 6.44% share declined -20.05% YoY and -4.67% MoM, and a tiny Edible presence at 0.02% share plunged -88.56% YoY but jumped 59.62% MoM. The mix implies Versus is shifting weight from high-ticket inhalables toward lower-priced formats as average price fell 34.80% YoY to $16.49 and Beverage gained momentum month over month, signaling a pivot toward value-led, repeatable use occasions where price elasticity is tighter and volume stability can offset unit-price compression.

These shifts reposition Versus toward beverages and value-tier pre-rolls that can defend share when premium inhalables retrench, evidenced by Beverage’s 2.32% MoM increase alongside steep MoM declines of -28.53% in Flower and -27.99% in Vapor Pens, and by Pre-Roll’s materially smaller YoY drop of -6.95% versus Flower’s -76.41%. With Beverage now at 20.82% share and Versus ranked 1 in Beverage in Ontario, the portfolio can leverage cannibalization away from Flower and Vapor Pens toward formats with steadier demand curves, implying a defend-and-harvest stance where price-led gains in Beverage and Pre-Roll cushion broader brand-level sales pressure of -58.32% YoY while preserving category leadership signaling and shelf presence.